http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
-
Voyager Therapeutics (VYGR) Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
-
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
-
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics (VYGR) Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
-
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
-
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
-
Voyager Therapeutics (VYGR) Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
-
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
-
Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
-
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
-
Voyager Therapeutics (VYGR) TRACER Capsids Demonstrate Enhanced CNS Transduction Across Species
-
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
-
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual M
-
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
-
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
-
Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
-
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences
-
Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
-
Voyager Therapeutics (VYGR) Reports Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program
-
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
-
Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
-
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
-
Voyager Therapeutics (VYGR) Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
-
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
-
Voyager Therapeutics (VYGR) Announces License Option Agreement with Pfizer (PFE) for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
-
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
-
Voyager Digital Partners with Football Star Rob Gronkowski to Expand Crypto Platform & Support Gronk Nation
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences
-
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
-
Voyager Therapeutics (VYGR) Announces Strategic Shift and Leadership Transitions
-
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
-
Voyager Therapeutics (VYGR) Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
-
Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
-
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
-
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
-
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
-
Voyager Therapeutics (VYGR) Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
-
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
-
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
-
Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
-
Voyager Therapeutics (VYGR) Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
-
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
-
Usio, Inc (USIO) Enters into Exclusive Contract with Leading Crypto Brokerage - Voyager Digital Holdings